Evaluation of evidence for the psychotic subtyping of post-traumatic stress disorder . Reduction in the N1 and P2 auditory event-related potentials in first-hospitalized and chronic schizophrenia . Reduced parietal P300 amplitude is associated with an increased risk for a first psychotic episode . Disability in people clinically at high risk of psychosis . Predictors of outcome in the early course of first-episode psychosis . Comparison of the effectiveness of depot-antipsychotics in routine clinical practice . Monitoring the metabolic side effects of atypical antipsychotics

Journal: S.S. Korsakov Journal of Neurology and Psychiatry. 2011;111(1): 115‑116

Downloaded: 5

Download PDF (RU)

Contact the author

Table of contents

To cite this article:

. Evaluation of evidence for the psychotic subtyping of post-traumatic stress disorder . Reduction in the N1 and P2 auditory event-related potentials in first-hospitalized and chronic schizophrenia . Reduced parietal P300 amplitude is associated with an increased risk for a first psychotic episode . Disability in people clinically at high risk of psychosis . Predictors of outcome in the early course of first-episode psychosis . Comparison of the effectiveness of depot-antipsychotics in routine clinical practice . Monitoring the metabolic side effects of atypical antipsychotics. S.S. Korsakov Journal of Neurology and Psychiatry. 2011;111(1):115‑116. (In Russ.)

Close metadata

Head tremor develops in one-third of patients with essential tremor. It is resistant to peroral antitremor medications. The efficacy of dysport, a botulinum toxin type A preparation, injected in the neck muscles, was examined in 12 patients with head tremor. After the injection of 500 U of the drug (150 U in each splenius muscle of the head and 100 U in each sternal-clavicular-mammiform muscle), the intensity of head tremor assessed by the rating tremor scale was decreased by more than 50%. The clinically significant effect was registrated in more than 2/3 of patients. Five patients who received repeated injections of dysport 2 times a year were followed-up for 3 years that allowed to find a trend towards the slow cumulative effect. The use of botulinum toxin type A preparations is recommended as a method of choice in patients with essential tremor and significant head tremor interfering with life activities.

List of references:

Golubev V.L. Tremor. Nevrol zhurn 2003; 2: 4-11.
Ivanova-Smolenskaya I.A. Klinicheskie varianty essentsial'nogo tremora. Zhurn nevropatol i psikhiat 1979; 3: 291-298.
Ivanova-Smolenskaya I.A. Drozhatel'nye giperkinezy. V kn.: Ekstrapiramidnye rasstroistva. Rukovodstvo po diagnostike i lecheniyu. Pod. red. V.N. Shtoka, I.A. Ivanovoi-Smolenskoi, O.S. Levina. M: MEDpress-inform 2002; 264-281.
Ivanova-Smolenskaya I.A., Rakhmonov R.A., Illarioshkin S.N. Essentsial'nyi tremor. Dushanbe: Poligraf-Grupp 2007.
Benito-Leon J., Louis E.D. Essential tremor: emerging views of a common disorder. Nat Clin Pract Neurol 2006; 2: 666-678.
Brin M.F., Lyons K.E., Doucette J. et al. A randomized, double masked, controlled trial of botulinum toxin type A in essential hand tremor. Neurology 2001; 56: 1523-1528.
Cleeves L., Findley L.J. Propranolol and propranolol-LA in essential tremor: a double bind comparative study. J Neurol Neurosurg Psychiatry 1988; 51: 379-384.
Deuschl G., Bain P.G., Brin M. Consensus statement of the Movement Disorder Society on Tremor. Ad hoc scientific committee. Mov Disord 1998; 13: Suppl 3: 2-3.
Jankovic J., Schwartz K. Botulinum toxin treatment of tremors. Neurology 1991; 41: 1185-1188.
Jankovic J., Schwartz K., Clemence W. et al. A randomized, double-blind, placebo-controlled study to evaluate botulinum toxin type A in essential hand tremor. Mov Disord 1996; 3: 250-256.
Jankovic J. Essential tremor: a heterogeneous disorder. Mov Disord 2002; 17: 638-644.
Koller W.C., Vetere-Overfield B. Acute and chronic effects of propranolol and primidone in essential tremor. Neurology 1989; 39: 1587-1588.
Louis E.D. Essential tremor. N Engl J Med 2001; 345: 887-891.
Louis E.D., Ottman R., Hauser W.A. How common is the most common adult movement disorder? Estimates of the prevalence of essential tremor throughout the world. Mov Disord 1998; 13: 5-10.
Louis E.D. Rios E., Henchcliffe C. How are we doing with the treatment of essential tremor (ET)? Persistence of patients with ET on medication: data from 528 patients in three settings. European Journal of Neurology 2010; 17: 882-884.
Pahwa R., Busenbark K., Swanson-Hyland E.F. et al. Botulinum toxin treatment of essential head tremor. Neurology 1995; 45: 822-824.
Sasso E., Perucca E., Fave R., Calzetti S. Primidone in the long term treatment of essential tremor: a perspective study with computerized quantitative analysis. Clin Neuropharmacol 1990; 13: 67-76.
Truong D., Dressler D., Hallett M. Manual of Botulinum Toxin Therapy. Cambridge University Press 2009; 195-204.
Zesiewicz T.A., Elble R., Louis E.D. et al. Practice parameter: therapies for essential tremor. Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 2005; 64: 2008-2020.

Close metadata